Karaman, AbdurrahmanSamdanci, EmineSayin, SadegulKarabulut, IsmailFadillioglu, Ersin2024-08-042024-08-0420130090-42951527-9995https://doi.org/10.1016/j.urology.2013.01.030https://hdl.handle.net/11616/96117OBJECTIVE To examine the efficacy of trospium chloride and tolterodine on the renal parenchymal inflammatory process and upper urinary dilation in rats with chronic partial upper urinary tract obstruction. MATERIALS AND METHODS A total of 32 rats were divided into 4 groups: group 1, control; group 2, obstruction; group 3, obstruction plus tolterodine; and group 4, obstruction plus trospium chloride. In all groups, except for group 1, partial upper urinary tract obstruction was induced by embedding the upper quarter of the right ureter into the psoas muscle for 14 days. At the end of the experiment, the rats were killed. The catalase, malondialdehyde, and protein carbonyl levels were determined in renal tissue. Tubular dilation and parenchymal inflammation were evaluated using hematoxylin-eosin staining. Smooth muscle actin and cytoglobin were examined with immunohistochemical staining. RESULTS The obstruction group demonstrated severe pelvic dilation and parenchymal inflammation and increased smooth muscle actin staining in the wall of upper urinary tract (P < .05). The treatment of the rats with tolterodine and trospium chloride markedly attenuated the inflammatory alterations and reduced tubular dilation. This treatment also reduced elevated oxidative stress product levels and restored the depleted renal antioxidant enzyme. CONCLUSION These findings imply that increased renal pelvic pressure can contribute to renal parenchymal injury in chronic pelvic upper urinary tract obstruction. Antimuscarinic medications such as tolterodine and trospium chloride exert renoprotective effects, probably by prevention of pelvic pressure increases. UROLOGY 82: 194-200, 2013. (C) 2013 Elsevier Inc.eninfo:eu-repo/semantics/closedAccessUreteropelvic Junction ObstructionUreteral ObstructionOveractive BladderOxidative StressPelvic PressuresSmooth-MuscleOxybutyninHydronephrosisExpressionDiagnosisArticle8211942002345364810.1016/j.urology.2013.01.0302-s2.0-84879555408Q2WOS:000321036200051Q2